Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PHOREVER

Financiado

Cerrado

PHOtonic integrated OCT-enhanced flow cytometry for canceR and cardiovascular di...

PHOtonic integrated OCT-enhanced flow cytometry for canceR and cardiovascular diagnostics enabled by Extracellular VEsicles discRimination Imaging tools such as the Computed Tomography (CT) and the Magnetic Resonance Imaging (MRI) can offer diagnosis of the cancer and the cardiovascular disease (CVD), but not insight into the molecular mechanisms that promote their o... ver más

30/06/2026

RESEARCH UNIVERSIT...

5M€

Presupuesto del proyecto: 5M€

Líder del proyecto

EREVNITIKO PANEPISTIMIAKO INSTITOUTO SYSTIMAT... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-01-01

HORIZON-CL4-2022-DIGITAL-EMERGING-01-30: European Enabling technologies for... ExpectedOutcome:Proposals are expected to contribute to all of the following expected outcomes:

I+D

Cerrada hace 2 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

RESEARCH UNIVERSITY INSTITUT...

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

uQuantEV Microfluidic EV Quantification for Point-of-Care CRC diagnos... 165K€ Cerrado

PDC2021-121444-I00 BIOSENSOR PARA MONITORIZACION DE BIOMARCADORES DE CANCER COL... 86K€ Cerrado

PID2019-110987RB-I00 UNA NUEVA PLATAFORMA DE DIAGNOSTICO DE BIOPSIA LIQUIDA: DETE... 157K€ Cerrado

NEXUS automated in-line separatioN and dEtection of eXtracellular... 2M€ Cerrado

PLATAFORMA DE BIOMARCADORES PREDICTIVOS PARA... PLATAFORMA DE BIOMARCADORES PREDICTIVOS PARA EL ESTUDIO PRE... 476K€ Cerrado

PLEC2021-007892 Plataforma (Oncodeeplasm) para inmunoensayos optoplasmónicos... 336K€ Cerrado

Duración del proyecto: 41 meses Fecha Inicio: 2023-01-01
Fecha Fin: 2026-06-30

Líder del proyecto

EREVNITIKO PANEPISTIMIAKO INSTITOUTO SYSTIMAT... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 5M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Imaging tools such as the Computed Tomography (CT) and the Magnetic Resonance Imaging (MRI) can offer diagnosis of the cancer and the cardiovascular disease (CVD), but not insight into the molecular mechanisms that promote their occurrence, progression and possible resistance to treatment. Information about these mechanisms is present however in the blood. Extracellular vesicles (EVs) are secreted into the blood, and can inform us about the state of their cells of origin, and by extension, about the presence and progression of diseases. Unfortunately, their detection is still imperfect due to the ultra-small size (50-200 nm) of most of them. PHOREVER will develop a disruptive multi-sensing platform that will enable for the first time the reliable detection of EVs with size down to 80 nm, the detection of EVs with specific biomarkers (proteins) on their surface, and the calculation of the corresponding EV concentrations in the blood. Its operation will be based on 3 sensing modalities: Flow-cytometry (FCM) with 4 wavelengths (405, 488, 633 and 785 nm) as the main modality for EV detection and size classification, dual-channel swept-source optical coherence tomography (SS-OCT) with 2.5 µm resolution for imaging of the sensing area and noise reduction of the FCM measurements, and fluorescence sensing at 488 nm for biomarker detection after staining. The key components will be the 2 photonic integrated circuits in TriPleX and the 3 microfluidic chips, which will be integrated as a compact point-of-care device. The medical impact can be ground-breaking. The first use case will be related to pancreatic cancer with focus on progression monitoring, metastasis risk assessment, and treatment efficacy evaluation. The second use case will be related to stroke with focus on its fast and precise diagnosis for time-to-treatment reduction. In either case, data analysis empowered by artificial intelligence will correlate the measurement data to disease specific medical information.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores